2023-12-11 13:00:00
Merck KGaA provided an update on phase III studies evaluating evobrutinib for the treatment of relapsing multiple sclerosis (MS). Neither trial met its primary endpoints. Among these criteria, the reduction in annualized relapse rates compared to oral teriflunomide, the reference treatment.
“With evobrutinib, our goal was to address the significant unmet need in latent MS, in addition to ensuring strict control of relapses in people living with this disease. Although we are very disappointed with the results, we continue to advance our strategy with a focus on advancing our internal portfolio and pipeline, complemented by external innovation, with the aim of delivering more medicines to patients , faster “commented Danny Bar-Zohar, global head of R&D at Merck.
Evobrutinib is a highly selective oral inhibitor of Bruton’s tyrosine kinase (BTK), which has the ability to penetrate the central nervous system (CNS). MS is a chronic inflammatory disease of the CNS, which affects approximately 2.8 million people worldwide.
The German laboratory’s portfolio in this pathology includes two compounds, Rebif (interferon beta-1a) and Mavenclad (cladribine). In 2022, these two products sold for €1.7 billion.
Selected for you
1702344693
#Merck #fails #phase #III #multiple #sclerosis
